SARS (Severe Acute Respiratory Syndrome - Coronaviruses)

Overview

Plain-Language Overview

SARS (Severe Acute Respiratory Syndrome) is a contagious viral illness that primarily affects the lungs and respiratory system. It is caused by a type of virus called a coronavirus, which can spread from person to person through respiratory droplets. The infection leads to symptoms such as fever, cough, and difficulty breathing, which can become severe and cause pneumonia. This illness can make it hard for people to breathe and may require hospitalization. The disease mainly impacts the lungs, causing inflammation and damage that interfere with normal breathing. It is important to understand that SARS can spread quickly in communities and healthcare settings.

Clinical Definition

SARS (Severe Acute Respiratory Syndrome) is an acute viral respiratory illness caused by the SARS-associated coronavirus (SARS-CoV). It is characterized by a rapid onset of fever, nonproductive cough, and dyspnea, often progressing to atypical pneumonia and acute respiratory distress syndrome (ARDS). The virus infects the respiratory epithelium, leading to diffuse alveolar damage and severe inflammation. Transmission occurs primarily via respiratory droplets and close contact. The disease has significant clinical importance due to its high morbidity and potential for outbreaks with substantial mortality. Diagnosis and containment are critical to prevent widespread transmission.

Inciting Event

  • Inhalation of respiratory droplets containing SARS coronavirus

  • Close contact with symptomatic or asymptomatic infected individuals

  • Exposure to contaminated surfaces followed by mucous membrane contact

  • Nosocomial transmission during aerosol-generating procedures

Latency Period

  • Incubation period typically ranges from 2 to 10 days

  • Median time to symptom onset is approximately 4-6 days

  • Asymptomatic viral shedding can occur during the incubation period

  • Symptom onset may be delayed in immunocompromised hosts

Diagnostic Delay

  • Initial symptoms mimic common viral illnesses leading to misdiagnosis

  • Lack of early specific diagnostic tests during outbreaks

  • Low clinical suspicion in non-epidemic settings

  • Overlap with other respiratory infections such as influenza or community-acquired pneumonia

Clinical Presentation

Signs & Symptoms

  • High fever (>38°C) is an early hallmark symptom.

  • Dry cough and dyspnea develop as the disease progresses.

  • Myalgia and malaise are common systemic symptoms.

  • Headache and chills often accompany the febrile phase.

  • Hypoxemia may manifest as cyanosis or respiratory distress in severe cases.

History of Present Illness

  • Initial presentation with high fever, chills, and malaise

  • Progressive dry cough and dyspnea developing over days

  • Myalgias and headache commonly reported early symptoms

  • Rapid progression to hypoxemia and respiratory distress in severe cases

  • Gastrointestinal symptoms such as diarrhea may occur in some patients

Past Medical History

  • History of chronic lung disease may worsen clinical course

  • Previous immunosuppressive therapy increases risk of severe infection

  • No specific genetic predisposition identified but comorbidities influence severity

  • Prior exposure to SARS or other coronaviruses may affect immune response

Family History

  • No known hereditary syndromes directly linked to SARS susceptibility

  • Clusters of cases within families due to close contact transmission

  • No evidence of genetic mutations increasing risk of infection

  • Family members often share environmental risk factors during outbreaks

Physical Exam Findings

  • Fever and tachypnea are common initial findings in SARS patients.

  • Crackles or rales may be auscultated due to viral pneumonia.

  • Hypoxia with decreased oxygen saturation is often present in severe cases.

  • Tachycardia may accompany systemic illness and hypoxia.

  • Lymphadenopathy is generally absent, helping differentiate from bacterial infections.

Diagnostic Workup

Diagnostic Criteria

Diagnosis is established by a combination of clinical presentation with fever, respiratory symptoms, and radiographic evidence of pneumonia or ARDS in a patient with relevant epidemiologic exposure. Confirmation requires detection of SARS-CoV RNA by RT-PCR from respiratory specimens or serologic evidence of infection. Chest imaging typically shows bilateral infiltrates consistent with viral pneumonia. Epidemiologic linkage to known cases or travel to endemic areas supports the diagnosis.

Pathophysiology

Key Mechanisms

  • Viral entry via binding of the SARS coronavirus spike protein to the ACE2 receptor on respiratory epithelial cells

  • Dysregulated immune response causing a cytokine storm with elevated IL-6, TNF-alpha, and other proinflammatory cytokines

  • Diffuse alveolar damage leading to acute respiratory distress syndrome (ARDS)

  • Endothelial injury and microvascular thrombosis contributing to pulmonary and systemic complications

  • Direct cytopathic effects of the virus on lung tissue causing epithelial cell apoptosis and necrosis

InvolvementDetails
Organs

Lungs are the primary organs affected, with diffuse alveolar damage causing respiratory distress

Lymph nodes show reactive hyperplasia reflecting immune activation during infection

Tissues

Alveolar epithelium is damaged by viral replication and immune-mediated injury, leading to impaired gas exchange

Endothelial tissue in pulmonary capillaries becomes inflamed, increasing vascular permeability and edema

Cells

Type II pneumocytes are the primary target cells for SARS coronavirus entry and replication in the lungs

Alveolar macrophages contribute to the inflammatory response and cytokine release in infected lung tissue

T lymphocytes mediate adaptive immune responses but may be depleted during severe infection

Chemical Mediators

Interleukin-6 (IL-6) is elevated and drives systemic inflammation and cytokine storm in severe SARS

Tumor necrosis factor-alpha (TNF-α) promotes lung tissue damage and vascular permeability

Interferon-gamma (IFN-γ) plays a role in antiviral defense but may contribute to immunopathology

Treatments

Pharmacological Treatments

  • Remdesivir

    • Mechanism:

      • Inhibits viral RNA-dependent RNA polymerase, blocking viral replication

    • Side effects:

      • Elevated liver enzymes

      • Nausea

      • Hypersensitivity reactions

    • Clinical role:

      • First-line

  • Corticosteroids

    • Mechanism:

      • Suppresses excessive immune response and inflammation in the lungs

    • Side effects:

      • Hyperglycemia

      • Immunosuppression

      • Psychiatric disturbances

    • Clinical role:

      • Adjunctive

  • Ribavirin

    • Mechanism:

      • Inhibits viral RNA synthesis and mRNA capping

    • Side effects:

      • Hemolytic anemia

      • Teratogenicity

      • Fatigue

    • Clinical role:

      • Second-line

Non-pharmacological Treatments

  • Supportive oxygen therapy to maintain adequate oxygenation in hypoxic patients

  • Mechanical ventilation for patients with respiratory failure or acute respiratory distress syndrome

  • Strict isolation and infection control measures to prevent nosocomial transmission

Prevention

Pharmacological Prevention

  • No approved antiviral prophylaxis exists for SARS coronavirus.

  • Post-exposure prophylaxis with investigational antivirals has limited evidence.

  • No licensed SARS vaccine is currently available.

Non-pharmacological Prevention

  • Strict isolation of suspected cases to prevent nosocomial spread.

  • Use of personal protective equipment (PPE) including N95 masks for healthcare workers.

  • Hand hygiene and respiratory etiquette reduce transmission risk.

  • Contact tracing and quarantine of exposed individuals are critical control measures.

  • Environmental disinfection of surfaces limits viral spread.

Outcome & Complications

Complications

  • Acute respiratory distress syndrome (ARDS) is the most serious complication.

  • Secondary bacterial pneumonia can occur during or after viral infection.

  • Multi-organ failure may develop in critically ill patients.

  • Sepsis and shock are potential life-threatening outcomes.

Short-term Sequelae Long-term Sequelae

  • Prolonged hypoxemia requiring supplemental oxygen or mechanical ventilation.

  • Pulmonary fibrosis may begin early in severe cases.

  • Muscle weakness and fatigue during recovery phase.

  • Psychological distress including anxiety and post-ICU syndrome.

  • Chronic pulmonary fibrosis leading to restrictive lung disease.

  • Persistent impaired lung function with reduced diffusion capacity.

  • Psychiatric disorders such as PTSD and depression post-recovery.

  • Exercise intolerance due to residual lung and muscle damage.

Differential Diagnoses

SARS (Severe Acute Respiratory Syndrome - Coronaviruses) versus Influenza

SARS (Severe Acute Respiratory Syndrome - Coronaviruses)

Influenza

Epidemic linked to travel or contact with affected regions, often outside typical flu season

Seasonal outbreaks with rapid community spread during winter months

Predominantly peripheral and lower lobe ground-glass opacities with occasional consolidation

Diffuse bilateral ground-glass opacities and patchy consolidations on chest imaging

Positive RT-PCR for SARS coronavirus RNA

Positive rapid influenza antigen or PCR test

SARS (Severe Acute Respiratory Syndrome - Coronaviruses) versus MERS (Middle East Respiratory Syndrome)

SARS (Severe Acute Respiratory Syndrome - Coronaviruses)

MERS (Middle East Respiratory Syndrome)

Exposure linked to southern China or Hong Kong outbreaks

Recent travel to or contact with persons from the Arabian Peninsula

Infection caused by SARS coronavirus

Infection caused by MERS coronavirus

Severe respiratory illness with lower incidence of renal involvement

Higher mortality rate with more frequent renal failure

SARS (Severe Acute Respiratory Syndrome - Coronaviruses) versus Community-acquired bacterial pneumonia

SARS (Severe Acute Respiratory Syndrome - Coronaviruses)

Community-acquired bacterial pneumonia

Normal or mildly elevated procalcitonin with lymphopenia

Elevated procalcitonin and neutrophilic leukocytosis

Diffuse interstitial infiltrates and ground-glass opacities

Lobar consolidation with air bronchograms on chest X-ray

No response to antibiotics; requires supportive care and antivirals

Rapid improvement with beta-lactam antibiotics

SARS (Severe Acute Respiratory Syndrome - Coronaviruses) versus Legionnaires' disease

SARS (Severe Acute Respiratory Syndrome - Coronaviruses)

Legionnaires' disease

Exposure to infected individuals or travel to SARS outbreak areas

Exposure to contaminated water sources such as air conditioning systems

Hyponatremia less common; lymphopenia more typical

Hyponatremia and elevated liver enzymes common

Positive RT-PCR for SARS coronavirus RNA

Positive urinary antigen test for Legionella pneumophila

SARS (Severe Acute Respiratory Syndrome - Coronaviruses) versus COVID-19 (Coronavirus Disease 2019)

SARS (Severe Acute Respiratory Syndrome - Coronaviruses)

COVID-19 (Coronavirus Disease 2019)

Exposure linked to SARS-CoV outbreak in early 2000s

Recent exposure to SARS-CoV-2 endemic areas or contacts

Infection caused by SARS-CoV coronavirus

Infection caused by SARS-CoV-2 coronavirus

Typically severe respiratory illness with shorter incubation period

Wider spectrum from asymptomatic to severe ARDS with longer incubation

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.

© 2026 Roscoe & Romano. All rights reserved.